Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P01189 (beta-endorphin)
 21,003 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The relative stability of natural melanotropins and related synthetic analogues to serum and purified proteolytic enzymes was studied. Both alpha- and beta-MSH were rapidly inactivated by frog serum, but much more slowly by rat serum. beta-MSH was more stable than alpha-MSH to serum inactivation. Both alpha- and beta-MSH were rapidly inactivated by alpha-chymotrypsin and trypsin. The synthetic analogues, [Nle4, D-Phe7]-alpha-MSH and [Cys4, Cys10]-alpha-MSH, were totally resistant to inactivation by frog and rat serum enzymes. [Nle4, D-Phe7]-alpha-MSH was resistant to inactivation by alpha-chymotrypsin and trypsin, whereas [Cys4, Cys10]-alpha-MSH was partially resistant to these enzymes under similar conditions. Melanotropin analogues resistant to inactivation by serum enzymes may prove useful in a variety of physiological studies wherein natural melanotropins would be rapidly inactivated.
 ...
PMID:Enzymological studies of melanotropins. 633 6

Biocytin derivatives of a superpotent analogue of alpha-melanotropin, [Nle4,D-Phe7]-alpha-MSH, were prepared. [N alpha-Bct-Ser1, Nle4,D-Phe7]-alpha-MSH and [12-Bct-N alpha-dodecanoyl-Ser1,Nle4,D-Phe 7]- alpha-MSH were synthesized by solid-phase techniques, and the coupling of biotin and 12-aminododecanoic acid was achieved through their succinimido esters. These melanotropins possessed almost identical actions to [Nle4,D-Phe 7]- alpha-MSH as determined by several melanocyte bioassays. Both biocytin derivatives were highly potent agonists and exhibited prolonged biological activity as determined in the frog and lizard skin bioassays. Both biotinylated peptides were at least equipotent to alpha-MSH in stimulating Cloudman S91 mouse melanoma tyrosinase activity. The analogues were resistant to inactivation by alpha-chymotrypsin.
 ...
PMID:Synthesis and biological actions of highly potent and prolonged acting biotin-labeled melanotropins. 643 88

The presence of a corticotropin-releasing factor (CRF) behaving as a peptide with a molecular weight of about 5000 was established after purification of porcine hypothalamic extracts by gel filtration on Sephadex G-25 and then on Sephadex G-50. Purified CRF stimulated the release of corticotropin (ACTH) in three in vitro systems: isolated rat pituitary quarters, monolayer cultures of dispersed pituitary cells, and superfused pituitary cells on a column. A linear logarithmic dose-response relationship existed between 50 and 200 micrograms of CRF preparations per ml and the total amount of ACTH released by the superfused pituitary cells. The pituitary ACTH response to CRF in the pituitary quarters system was also approximately linearly related to the logarithm of the dose of CRF. CRF also stimulated in vivo release of ACTH in rats pretreated with chlorpromazine, morphine, and Nembutal. CRF activity was labile to digestion with trypsin and chymotrypsin and was partially destroyed by pepsin. The evidence indicates that CRF of porcine origin is a polypeptide of a higher molecular weight than previously assumed.
 ...
PMID:High molecular weight peptide with corticotropin-releasing factor activity from porcine hypothalami. 697 79

Rat intermediate pituitary cells maintained in culture synthesize the same forms of beta-endorphin observed in intermediate pituitary extracts. Biosynthetically labeled intermediate pituitary beta-endorphin-sized material was fractionated by ion exchange chromatography on sulfopropyl-Sephadex and the identities of the major peaks were determined by co-chromatography with synthetic marker peptides, gel filtration, and analysis of pronase, chymotrypsin, and trypsin digests. Peaks of alpha-N-acetyl-beta-endorphin(1-27), alpha-N-acetyl-beta-endorphin(1-31), and beta-endorphin(1-31) were identified and a fourth peak (eluting from the sulfopropyl-Sephadex column at 0.18 M NaCl) was tentatively identified as alpha-N-acetyl-beta-endorphin(1-26). Analysis of beta-endorphin synthesized in the presence of [35S]methionine and [3H]histidine confirmed the absence of His in the material eluting at 0.18 M NaCl. Based on both steady labeling and pulse-chase incubations, beta-endorphin(1-31) was the first form of labeled beta-endorphin-sized material to appear in cell extracts. This molecule was quickly N-acetylated on its NH2-terminal tyrosine residue and was then more slowly converted to alpha-N-acetyl-beta-endorphin(1-27) and then to alpha-N-acetyl-beta-endorphin(1-26).
 ...
PMID:Further analysis of post-translational processing of beta-endorphin in rat intermediate pituitary. 724 Jan 66

The stability of tert-butoxycarbonyl-Tyr-Leu-Val-CH2Cl (YLV) with inhibitory effect on human leukocyte elastase was investigated in aqueous solution, alpha-chymotrypsin solution and biological media. In all cases studied here, the degradation was observed as a pseudo-first order reaction. The half-life for the degradation of YLV in an aqueous solution of pH 7.4 at 37 degrees C was 35.9 h. YLV was most stable at about pH 3.8-5.8 and the effect of temperature was explained by the Arrhenius equation. The activation energies of the degradation in aqueous solutions at pH 2.0, 4.8, and 7.4 were 24.6, 22.1 and 23.4 kcal/mol, respectively. The degradation products in aqueous solution were analyzed by HPLC-MS and were estimated as Boc-Tyr-Leu-Val-CH2OH at pH 7.4 and H2N-Tyr-Leu-Val-CH2Cl at pH 2.0. In a bovine pancreas alpha-chymotrypsin solution at 37 degrees C, the half-life of YLV was 15 min at 25.6 micrograms/ml of alpha-chymotrypsin solution. In the rat plasma, the half-life of YLV was 42.4 min (YLV 26.7 micrograms/ml plasma), and in rat liver, lung and spleen homogenates, the degradation rate constants of YLV were 37.6, 10.3 and 23.5 times larger than that in plasma solution, respectively (all fluids containing 5 mg protein/ml). YLV was less stable than nafarelin acetate, secretin, adrenocorticotropic hormone (ACTH) and gonadorelin in an aqueous solution of pH 7.4.
 ...
PMID:Degradation of a novel tripeptide, tert-butoxycarbonyl-Tyr-Leu-Val-CH2Cl, with inhibitory effect on human leukocyte elastase in aqueous solution and in biological fluids. 939 62

Ovoinhibitor is a serine protease-inhibiting protein that was originally purified from egg whites. It is secreted by the oviduct under the control of estrogen and progesterone and it specifically inhibits serine proteinases such as trypsin and chymotrypsin. During recent attempts to raise monoclonal antibodies (Mabs) against chicken bursa of Fabricius proteins, one Mab was produced that specifically recognized chicken ovoinhibitor. This was the first demonstration of ovoinhibitor in an avian immune organ. We presently report on the expression of an ovoinhibitor-like molecule by the pituitary of the chicken as revealed by immunocytochemistry and RT-PCR. Immunofluorescent dual staining experiments using the mouse anti-ovoinhibitor Mab in conjunction with polyclonal antibodies against various hypophysial hormones revealed partial co-localization of an ovoinhibitor-like molecule with growth hormone (GH), luteinizing hormone (LH), and pro-opiomelanocortin (POMC), in a subset of the respective hormone producing cells. By contrast, no co-localization with prolactin (PRL) could be reliably demonstrated. RT-PCR of hypophysial mRNA using ovoinhibitor gene-specific primers yielded an amplicon that was 20% shorter than predicted on the basis of the published ovoinhibitor sequence. Sequencing revealed that of the represented exons only the central portion was expressed in the pituitary and that both 5' and 3' ends of each exon had been truncated. While expression of ovalbumin-like serine protease inhibitors (serpins) has been previously reported in the rat pituitary, to our knowledge, this is the first report of a Kazal-type serine protease inhibitor in the vertebrate neuroendocrine system.
 ...
PMID:The chicken pituitary expresses an ovoinhibitor-like protein in subpopulations of some, but not all, hormone-producing cell types. 1465 38

Ectoine, a zwitterionic compatible solute (CS), acts as an effective stabilizer of protein function. Using molecular dynamics simulation, solvent spatial distributions around both met-enkephalin (M-Enk) and chymotrypsin inhibitor 2 (CI2) were investigated at the molecular level in ectoine aqueous solution. An unexpected finding was that ectoine exhibits preferential binding, as an overall tendency, around both peptides. However, with the aid of the surficial Kirkwood-Buff parameter, it was clearly shown that the preferential exclusion of ectoine from the peptide surface was weaker in the smaller M-Enk than in the larger CI2. It is concluded that a denser and more structured hydration layer, such as that developed on the surface of CI2, is an important factor in the exclusion of ectoine.
 ...
PMID:Microscopic understanding of preferential exclusion of compatible solute ectoine: direct interaction and hydration alteration. 1767 87


<< Previous 1 2